ProjektportalTheranostics for prostate cancer: Combined targeted radionuclide imaging and therapy
Terrmin
HT23
Beskrivning
There is a clinical need to improve further therapy of prostate cancer PCa. Research i Theranostics group provides scientific rationale for the use of theranostics for therapy of prostate cancer. The theranostics approach includes radionuclide imaging of molecular targets, i.e. receptors and antigens closely associated with prostate cancer progression (e.g. prostate-specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR), and members of receptor tyrosine kinase (RTK) family, EGFR, HER2, HER3, IGF-1R) in combination with therapy specific to these targets.
The aim of our research is to obtain knowledge permitting the use of molecular targeting for radionuclide diagnostic and therapy of disseminated prostate cancer. We develop and evaluate short radiolabelled synthetic peptides targeting GRPR and PSMA as well as bispecific peptides targeting simultaneously PSMA and GRPR for imaging and therapy of prostate cancer metastases. we evaluate factors influencing targeting properties and therapeutic efficacy of scaffold protein-based constructs against RTK for targeting therapy of prostate cancer. We develop and evaluate affibody-based companion imaging probes enabling prostate cancer patient stratification for RTK targeted therapy.
Huvudområde
Läkemedelsutveckling
Ämne
Molekylär avbildning
Typ
Laborativ studie
Företag
Uppsala University
Ort/Plats
Uppsala
Handledarens namn
Anna Orlova
Handledarens e-post
anna.orlova@ilk.uu.se
Institution
Institutionen för Läkemedelskemi
Program
Masterprogram i läkemedelsutveckling
Kurs
Degree Project in Drug Discovery and Development 30 c - 3FK045
Omfattning/hp
45hp
Hur många studenter kan antagas för detta projekt?
1